Evaluation Of Serum Level Of Pentraxin 3 As A Biomarker For Prediction Of Gestational Diabetes Mellitus

Background: Gestational diabetes mellitus is associated with adverse perinatal outcome. Screening for gestational diabetes mellitus and applying adequate interventions may reduce the risk of adverse outcome. However, the diagnosis of gestational diabetes mellitus depends largely on test performed in late second trimester. The discovery of new biomarker buildup a simple model to predict gestational diabetes mellitus in early pregnancy one of them is Pentraxin 3. Objective: In this study we aimed, to evaluate the potential relationship between Pentraxin 3 and occurrence of gestational diabetes at 24-28 weeks of gestation and to evaluate the significance of Pentraxin 3 as early predictor of gestational diabetes. Study design: prospective case-control study. Setting: Department of Obstetrics and Gynecology, Al-Yarmouk Teaching Hospital, Baghdad / Iraq. Patient and methods: The study involved 150 pregnant women with singleton pregnancy, 75 of them with risk factors for gestational diabetes mellitus as a case group( group 1) and the other group have no risk factor as a control group (group 2) Each participant was given an appointment at 14-18 weeks of gestation .Blood sample was taken from all after fasting for 8 –hours. Unfortunately, we missed a lot of them. However Pentraxin 3 concentration, fasting plasma glucose, glycosylated hemoglobin and fasting plasma insulin were all tested and analyzed subsequently to those who continue the study. Furthermore, there was another appointment at 24—28 weeks of gestation for 75 g OGTT. Results: Pentraxin 3 was significantly higher in participants of Group (1) who had risk factors (p-value=0.01) .And there is significant association between high body mass index and gestational diabetes mellitus of a p-value 0.05. Oral glucose tolerance test was significantly higher on first, second and third readings in Group (1) who had risk factor (p value were 0.028, 0.05 and 0.01 respectively). Conclusion: Serum Pentraxin 3 level was significantly higher in patient with gestational diabetes mellitus, The increase in oral glucose tolerance test was significant associated with an increase in the PTX-3. Keywords : gestational diabetes mellitus, biomarkers, pregnancy

Authors

Publication Details

Journal
Journal of Clinical Obstetrics and Gynecology Research
Published
2025-04-26
DOI
https://doi.org/10.52338/jocogr.2025.4606
Primary Topic
Biomarkers in Disease Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation Of Serum Level Of Pentraxin 3 As A Biomarker For Prediction Of Gestational Diabetes Mellitus

Said Sami, N. Goyal Sameer, Fatin shallal
Journal of Clinical Obstetrics and Gynecology Research
Biomarkers in Disease Mechanisms
article

Evaluation Of Serum Level Of Pentraxin 3 As A Biomarker For Prediction Of Gestational Diabetes Mellitus

Said Sami, N. Goyal Sameer, Fatin shallal
article en

Abstract

Background: Gestational diabetes mellitus is associated with adverse perinatal outcome. Screening for gestational diabetes mellitus and applying adequate interventions may reduce the risk of adverse outcome. However, the diagnosis of gestational diabetes mellitus depends largely on test performed in late second trimester. The discovery of new biomarker buildup a simple model to predict gestational diabetes mellitus in early pregnancy one of them is Pentraxin 3. Objective: In this study we aimed, to evaluate the potential relationship between Pentraxin 3 and occurrence of gestational diabetes at 24-28 weeks of gestation and to evaluate the significance of Pentraxin 3 as early predictor of gestational diabetes. Study design: prospective case-control study. Setting: Department of Obstetrics and Gynecology, Al-Yarmouk Teaching Hospital, Baghdad / Iraq. Patient and methods: The study involved 150 pregnant women with singleton pregnancy, 75 of them with risk factors for gestational diabetes mellitus as a case group( group 1) and the other group have no risk factor as a control group (group 2) Each participant was given an appointment at 14-18 weeks of gestation .Blood sample was taken from all after fasting for 8 –hours. Unfortunately, we missed a lot of them. However Pentraxin 3 concentration, fasting plasma glucose, glycosylated hemoglobin and fasting plasma insulin were all tested and analyzed subsequently to those who continue the study. Furthermore, there was another appointment at 24—28 weeks of gestation for 75 g OGTT. Results: Pentraxin 3 was significantly higher in participants of Group (1) who had risk factors (p-value=0.01) .And there is significant association between high body mass index and gestational diabetes mellitus of a p-value 0.05. Oral glucose tolerance test was significantly higher on first, second and third readings in Group (1) who had risk factor (p value were 0.028, 0.05 and 0.01 respectively). Conclusion: Serum Pentraxin 3 level was significantly higher in patient with gestational diabetes mellitus, The increase in oral glucose tolerance test was significant associated with an increase in the PTX-3. Keywords : gestational diabetes mellitus, biomarkers, pregnancy

Journal of Clinical Obstetrics and Gynecology ResearchVol. 10(1)
Openalex Percentile: Top 90%
Biomarkers in Disease Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.